Intelligence Profile
Research Papers
The research on Cartalax consists of laboratory studies examining its effects on cellular processes, with no clinical trials identified in humans. Here's what the current evidence shows:
Stem Cell and Aging Research
A 2020 study published in Molecular Biology Reports investigated how Cartalax affects gene expression in aging human mesenchymal stem cell cultures. The researchers found that short peptides, including Cartalax, could modulate genetic activity in these aging cells, though specific sample sizes and detailed methodologies were not provided in the abstract.
A 2019 study in the International Journal of Immunopathology and Pharmacology examined Cartalax's impact on stem cell differentiation into neurons. The research suggested that short peptides like Cartalax may influence how stem cells develop into nerve cells, but again, detailed study parameters are not available from the abstract alone.
Tissue-Specific Studies
Several laboratory studies have examined Cartalax's effects on specific tissue types:
A 2016 study in the Bulletin of Experimental Biology and Medicine looked at skin fibroblast function during aging in laboratory cultures, finding that peptides could regulate cellular processes in aging skin cells.
Two kidney-focused studies (2015 and 2014) published in similar journals examined cellular renewal processes in kidney tissue cultures from both young and old animals, with one study specifically noting that tripeptides could slow aging processes in kidney cell cultures.
A 2011 study investigated peptide regulation of immune cell (thymocyte) processes in the thymus during aging.
Study Limitations
All available research appears to be conducted in laboratory settings using cell cultures or animal tissue, with no human clinical trials identified. The studies generally lack detailed information about sample sizes, specific methodologies, or statistical significance in their abstracts. Most research comes from a limited number of journals and appears to focus on basic cellular mechanisms rather than clinical applications.
This represents very early-stage research that has not progressed to human testing. More robust clinical studies would be needed to determine safety and efficacy in humans.